hydrazine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Gai, Y; Ji, H; Jiang, D; Lan, X; Liu, Q; Long, Y; Pan, Z; Qin, C; Shao, F; Song, W; Song, X; Song, Y; Wang, K; Zhu, J; Zhu, K; Zhu, Z | 1 |
| Argueta, C; Croce, A; Daidone, MG; De Marco, C; Figini, M; Frigerio, B; Gianni, AM; Landesman, Y; Martini, S; Pennati, M; Satta, A; Zaffaroni, N | 1 |
| Ouyang, L; Pluta, R; Wang, G; Xu, T; Yang, C; Ye, T; Zhang, J | 1 |
| Fu, L; Guo, M; Ouyang, L; Wang, P; Wang, S; Wang, X; Yao, D; Zhang, L; Zheng, Y | 1 |
| Akcakanat, A; Arango, NP; Evans, KW; Gonzalez-Angulo, AM; Janku, F; Kim, C; Meric-Bernstam, F; Naing, A; Scott, S; Tripathy, D; Ueno, NT; Yuca, E; Zhao, M | 1 |
| Boulware, D; Extermann, M; Goodridge, D; Han, HS; Hogue, D; Ismail-Khan, R; Khong, H; Shafique, M; Soliman, H; Sullivan, D | 1 |
| Abdel-Aziz, HA; Al-Ansary, GH; Al-Dhfyan, A; Almahli, H; Aly, MH; Eldehna, WM; Ghabbour, HA; Ismael, OE | 1 |
1 trial(s) available for hydrazine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Rate; Triazoles; Triple Negative Breast Neoplasms | 2019 |
6 other study(ies) available for hydrazine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Humans; Hydrazines; Immunoconjugates; Indocyanine Green; Nectins; Nicotinic Acids; Photothermal Therapy; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution; Triple Negative Breast Neoplasms | 2022 |
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Topics: Antibodies, Bispecific; Cell Line, Tumor; Female; Humans; Hydrazines; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer.
Topics: Apoptosis; Autophagy; Binding Sites; Cell Line, Tumor; Cell Survival; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Hydrazines; Molecular Docking Simulation; Protein Kinase Inhibitors; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2021 |
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dibenzoxepins; Drug Design; Humans; Hydrazines; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Transplantation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2016 |
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Doxorubicin; Female; Furans; Humans; Hydrazines; Ketones; MCF-7 Cells; Mice; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydrazines; In Vitro Techniques; Isatin; Phthalazines; Triple Negative Breast Neoplasms | 2017 |